TIMI 11B

TIMI 11B evaluated the safety and efficacy of subcutaneous enoxaparin compared with unfractionated heparin for the treatment of patients presenting with unstable angina or non-Q-wave myocardial infarction.

MAIN RESULTS:
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction
TIMI 11B
Circulation. 1999 Oct 12;100(15):1593-601.

PRESENTATIONS

TIMI 11B Slides

PUBLICATIONS

Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators. Am Heart J. 1998 Jun;135(6 Pt 3 Su):S353-60.

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999 Oct 12;100(15):1602-8.

Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. Clin Chem. 2000 Apr;46(4):453-60.

The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000 Aug 16;284(7):835-42.

Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction. Am J Cardiol. 2000 Sep 1;86(5):553-6, A9.

Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time. Am Heart J. 2000 Oct;140(4):637-42.

Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol. 2000 Nov 15;36(6):1812-7.

Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. Am Heart J. 2001 Apr;141(4):566-72.

A simple, readily available method for risk stratification of patients with unstable angina and non-ST elevation myocardial infarction.Am J Cardiol. 2001 Apr 15;87(8):1008-10; A5.

Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Am Heart J. 2001 Oct;142(4):590-3.

Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups. J Thromb Thrombolysis. 2001 Dec;12(3):199-206.

Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes. Am Heart J. 2002 Jan;143(1):63-9.

Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J. 2002 Feb;23(4):308-14.

Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Eur Heart J. 2002 Feb;23(3):223-9.

An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002 Feb;23(3):223-9.

Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002 Feb 15;89(4):463-5.

Superiority of enoxaparin over unfractionated heparin for the treatment of acute coronary syndromes. Pharmacotherapy. 2002 Apr;22(4):542-6.

Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2002 May;143(5):753-9.

Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J. 2002 Jun;143(6):966-70.

The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. J Am Coll Cardiol. 2002 Jul 17;40(2):238-44

Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J.
2003 Jul;146(1):33-41.

Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004 Jul 7;292(1):89-96.

Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 Nov;25(22):1998-2005.

Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich) . 2006 May;8(5):315-22.

Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. Am J Cardiol. 2007 Dec 15;100(12):1734-8.

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close